Skip to content

Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work, and whether you can afford to take the high risk of losing your money.
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work, and whether you can afford to take the high risk of losing your money.

What next for Unilever shares?

It’s been a rough month for Unilever after its failed takeover of GSK’s healthcare business, but could an activist investor drive a revival?

Unilever Source: Bloomberg

The drama continues at Unilever PLC as, following its abortive bid for Glaxo’s healthcare division, it was revealed that US investor Nelson Peltz has taken a stake in the company. Shares in the food producer rose 6% on news that the activist shareholder has built up a holding in the owner of Marmite and Magnum ice cream via his vehicle, Trian. Peltz is known for taking a position at Unilever rival Procter & Gamble and working with the management to make improvements after a long-running battle to secure a seat on the board.

A major setback

Unilever is licking its wounds post three failed bids – the final one worth £50bn for Glaxo'shealthcare arm, which includes Sensodyne and Advil. Chief executive Alan Jope insisted the business was a “strong strategic fit” and that it would create new opportunities in emerging markets.

He told investors that Unilever’s future lies in “materially expanding its presence in health, beauty, and hygiene,” which he believes offers “higher rates of sustainable market growth.”

However, Glaxo and Pfizer Inc (All Sessions), who own the healthcare business, and Unilever’s investors had other ideas. Glaxo’s board said the bids “fundamentally undervalued” its business, while Unilever’s shareholders had concerns over the scale and workability of the deal, which would have been one of the biggest ever seen in the London market.

Fund manager Terry Smith described the failed deal as a “near-death experience, while analysts at Bernstein Bank predicted it would deliver £10bn of “value destruction” for shareholders.

Unilever shares dropped to a year low of 3516p – down 32% since 2019.

Where does Unilever go from here?

Jope says he is “committed to accelerating the company’s growth and repositioning the portfolio into higher growth categories.” In the meantime, he has announced it is to restructure, cutting 1500 jobs worldwide, including 15% of senior management and 5% of junior management positions. It is axing its matrix structure and reorganising around five business groups: beauty and wellbeing, personal care, home care, nutrition and ice cream.

“Moving to five category-focused business groups will enable us to be more responsive to consumer and channel trends, with crystal-clear accountability for delivery,” said Jope. “Growth remains our top priority and these changes will underpin our pursuit of this.”

But will this be enough to placate shareholders? Recovering some ground to 3820p, the shares have lost 26% of their value since peaking at 5196p in August 2019.

Activist Marmite

Love them or hate them, activist investors can sometimes lead change. Could Unilever’s investors see Peltz work his magic? After the activist hedge fund manager took a stake in Procter & Gamble in 2018, and the share price doubled from around 75p to 150p by 2020.

Martin Deboo, analyst at Jefferies, expects Trian to push for breaking up parts of Unilever and spinning them out. “We have long been of the view that the right path to unlock value at Unilever is via a faster rate of disposals from its slow-growing foods businesses, or a separation between foods and household and personal care, via a sale or spin [out],” he said in a note, adding that the “fox would now appear to be inside the henhouse.”

Meanwhile, analysts at Barclays said in a note, “from Unilever’s perspective, the status quo is not an option. It would seem that the stars are aligning with both Unilever management and an activist pushing for more urgency.”

With fourth quarter figures due on February 10th, investors could find out more soon.

Trade what you want, when you want with the UK’s No.1 trading provider.* We have over 80 top global indices with more trading hours than anyone else. Find out more about indices trading or open an account to trade now.

*Based on revenue (published financial statements, 2022).

This information has been prepared by IG, a trading name of IG Markets Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients. See full non-independent research disclaimer and quarterly summary.

Act on share opportunities today

Go long or short on thousands of international stocks with spread bets and CFDs.

  • Get full exposure for a comparatively small deposit
  • Trade on spreads from just 0.1%
  • Get greater order book visibility with direct market access

See opportunity on a stock?

Try a risk-free trade in your demo account, and see whether you’re on to something.

  • Log in to your demo
  • Take your position
  • See whether your hunch pays off

See opportunity on a stock?

Don’t miss your chance – upgrade to a live account to take advantage.

  • Trade a huge range of popular stocks
  • Analyse and deal seamlessly on fast, intuitive charts
  • See and react to breaking news in-platform

See opportunity on a stock?

Don’t miss your chance. Log in to take advantage while conditions prevail.

Live prices on most popular markets

  • Equities
  • Indices
  • Forex
  • Commodities


Prices above are subject to our website terms and agreements. Prices are indicative only. All share prices are delayed by at least 15 minutes.

Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 15 mins.

Plan your trading week

Get the week’s market-moving news sent directly to your inbox every Sunday. The Week Ahead gives you a full calendar of upcoming economic events, as well as commentary from our expert analysts on the key markets to watch.


For more info on how we might use your data, see our privacy notice and access policy and privacy webpage.

You might be interested in…

Find out what charges your trades could incur with our transparent fee structure.

Discover why so many clients choose us, and what makes us a world-leading provider of spread betting and CFDs.

Stay on top of upcoming market-moving events with our customisable economic calendar.